Extended thromboprophylaxis for hip or knee arthroplasty. Does the administration route and dosage regimen affect adherence? A cohort study
Purpose: Prevention of thromboembolic disease requires patients’ adherence to the extended thromboprophylaxis scheme. Oral anticoagulants are expected to improve adherence as a result of their route of administration; however, this assumption is yet to be confirmed. The purpose of this study was to...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2020
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/22169
- Acceso en línea:
- https://doi.org/10.1007/s00264-019-04454-3
https://repository.urosario.edu.co/handle/10336/22169
- Palabra clave:
- Apixaban
Enoxaparin
Rivaroxaban
Adolescent
Adult
Aged
Article
Body mass
Cohort analysis
Controlled study
Drug administration route
Drug cost
Drug dose regimen
Drug withdrawal
Epistaxis
Female
Follow up
Health status
Hip arthroplasty
Hip fracture
Human
Knee arthroplasty
Major clinical study
Male
Medication compliance
Osteoarthritis
Patient compliance
Practice guideline
Prescription
Priority journal
Prospective study
Thrombosis prevention
Venous thromboembolism
Arthroplasty
Hip
Prevention and control
Replacement
Venous thromboembolism
- Rights
- License
- Abierto (Texto Completo)
Summary: | Purpose: Prevention of thromboembolic disease requires patients’ adherence to the extended thromboprophylaxis scheme. Oral anticoagulants are expected to improve adherence as a result of their route of administration; however, this assumption is yet to be confirmed. The purpose of this study was to assess the impact of the route of administration and dosage regimen on the compliance to the prescription. Materials and methods: This prospective cohort study included hip and knee arthroplasty patients who received pharmacological extended thromboprophylaxis with one daily injection, one daily oral tablet, or two daily oral tablets. A telephonic questionnaire was applied 35 days after the day of the surgery. Patients who omitted one or more doses of medication during the follow-up period were classified as “non-adherent.” Differences of adherence rates were assessed. Results: Five hundred and twenty patients were included: 153 received Apixaban (oral, twice a day), 155 Enoxaparin (injectable, once a day), and 212 Rivaroxaban (oral, once a day). Patients receiving oral once a day medication was more compliant compared with those who received an oral medication twice a day. Non-adherence rates were 3.2 and 9.2%, respectively (p = 0.033). No significant differences (p = 0.360) were found between oral once a day and injectable once a day medication. Conclusions: The number of daily doses prescribed was related to adherence to extended chemical prophylaxis, while the route of administration did not seem to have a significant impact. Strategies to promote outpatient compliance must be implemented, especially when regimes including more than one daily dose are prescribed. © 2019, SICOT aisbl. |
---|